Everything below concerns Research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
=== Prescription trends === In 2010, over 24.4 million prescriptions for generic fluoxetine were filled in the United States, making it the third-most prescribed antidepressant after sertraline and citalopram. In 2011, 6 million prescriptions for fluoxetine were filled in the United Kingdom. Between 1998 and 2017, along with amitriptyline, it was the most commonly prescribed first antidepressant for adolescents aged 12–17 years in England.
This makes it a highly effective treatment for negative and cognitive symptoms of schizophrenia since 5HT2A antagonism increases dopamine release in the mesocortical pathway which is hypoactive in those with schizophrenia. Interestingly, lumateperone indirectly augments glutamatergic neurotransmission through its activity at D1 receptors, which causes phosphorylation of GluN2B subunits of NMDA receptors in the mesolimbic pathway. This is significant since NMDA receptor hypofunction, reduced D1 binding, and glutamatergic abnormalities have been implicated in contributing to the cognitive and negative symptoms of schizophrenia. It has also been identified as a potent vesicular monoamine transporter 2 (VMAT2) inhibitor (IC50Tooltip half-maximal inhibitory concentration = 62 nM).
In any case, enobosarm has been demonstrated to have varying full agonist or partial agonist or antagonist actions in specific tissues, including potent agonistic and anabolic effects in muscle and bone, potent agonistic effects in AR-expressing human breast cancer cell lines like MCF-7 and MDA-MB-231, and partially agonistic or antagonistic effects in the prostate gland, seminal vesicles, and uterus. Enobosarm has additionally been shown to stimulate sexual motivation in female rats similarly to testosterone. Although enobosarm has not been specifically assessed in this area, another structurally unrelated quinolinone SARM, LGD-2226, has shown prosexual effects in male rats comparable to those of the synthetic androgen and anabolic steroid fluoxymesterone as well. The molecular mechanisms underlying the tissue-selective effects of enobosarm and other SARMs compared to testosterone and other androgens and anabolic steroids remain unknown. However, recruitment of both coactivators and corepressors instead of only coactivators and resultant differing receptor conformations, distinct tissue-specific modulation of signaling pathways mediating genomic and non-genomic effects, and differences in within-tissue ligand metabolism and modulation of ligand potency (i.e., potentiation versus lack thereof), among others, all constitute possible mechanisms.
Sources: en.wikipedia.org
==== MeSH D13.444.735 – rna ==== MeSH D13.444.735.130 – rna, algal MeSH D13.444.735.150 – rna, antisense MeSH D13.444.735.150.319 – micrornas MeSH D13.444.735.150.640 – oligoribonucleotides, antisense MeSH D13.444.735.150.700 – rna, small interfering MeSH D13.444.735.300 – rna, archaeal MeSH D13.444.735.473 – rna, bacterial MeSH D13.444.735.476 – rna, chloroplast MeSH D13.444.735.480 – rna, complementary MeSH D13.444.735.490 – rna, double-stranded MeSH D13.444.735.500 – rna, fungal MeSH D13.444.735.520 – rna, helminth MeSH D13.444.735.544 – rna, messenger MeSH D13.444.735.544.355 – codon MeSH D13.444.735.544.355.225 – codon, initiator MeSH D13.444.735.544.355.250 – codon, terminator MeSH D13.444.735.544.355.250.235 – codon, nonsense MeSH D13.444.735.544.500 – rna caps MeSH D13.444.735.544.500.710 – rna cap analogs MeSH D13.444.735.544.527 – rna, messenger, stored MeSH D13.444.735.544.550 – rna splice sites MeSH D13.444.735.544.875 – untranslated regions MeSH D13.444.735.544.875.880 – 3' untranslated regions MeSH D13.444.735.544.875.885 – 5' untranslated regions MeSH D13.444.735.615 – rna, neoplasm MeSH D13.444.735.628 – rna, nuclear MeSH D13.444.735.628.806 – rna, heterogeneous nuclear MeSH D13.444.735.628.818 – rna, small nuclear MeSH D13.444.735.628.818.800 – rna, small nucleolar MeSH D13.444.735.635 – rna, plant MeSH D13.444.735.635.575 – rna, chloroplast MeSH D13.444.735.640 – rna precursors MeSH D13.444.735.650 – rna, protozoan MeSH D13.444.735.686 – rna, ribosomal MeSH D13.444.735.686.650 – rna, ribosomal, 5s MeSH D13.444.735.686.660 – rna, ribosomal, 5.8s MeSH D13.444.735.686.670 – rna, ribosomal, 16s MeSH D13.444.735.686.675 – rna, ribosomal, 18s MeSH D13.444.735.686.680 – rna, ribosomal, 23s MeSH D13.444.735.686.690 – rna, ribosomal, 28s MeSH D13.444.735.686.845 – rna, ribosomal, self-splicing MeSH D13.444.735.721 – rna, satellite MeSH D13.444.735.721.250 – cucumber mosaic virus satellite MeSH D13.444.735.757 – rna, transfer MeSH D13.444.735.757.286 – anticodon MeSH D13.444.735.757.700 – rna, transfer, amino acid-specific MeSH D13.444.735.757.700.050 – rna, transfer, ala MeSH D13.444.735.757.700.075 – rna, transfer, arg MeSH D13.444.735.757.700.085 – rna, transfer, asn MeSH D13.444.735.757.700.090 – rna, transfer, asp MeSH D13.444.735.757.700.200 – rna, transfer, cys MeSH D13.444.735.757.700.400 – rna, transfer, gln MeSH D13.444.735.757.700.410 – rna, transfer, glu MeSH D13.444.735.757.700.420 – rna, transfer, gly MeSH D13.444.735.757.700.450 – rna, transfer, his MeSH D13.444.735.757.700.480 – rna, transfer, ile MeSH D13.444.735.757.700.500 – rna, transfer, leu MeSH D13.444.735.757.700.510 – rna, transfer, lys MeSH D13.444.735.757.700.525 – rna, transfer, met MeSH D13.444.735.757.700.650 – rna, transfer, phe MeSH D13.444.735.757.700.660 – rna, transfer, pro MeSH D13.444.735.757.700.700 – rna, transfer, ser MeSH D13.444.735.757.700.725 – rna, transfer, thr MeSH D13.444.735.757.700.740 – rna, transfer, trp MeSH D13.444.735.757.700.750 – rna, transfer, tyr MeSH D13.444.735.757.700.900 – rna, transfer, val MeSH D13.444.735.757.715 – rna, transfer, amino acyl MeSH D13.444.735.790 – rna, untranslated MeSH D13.444.735.790.099 – micrornas MeSH D13.444.735.790.149 – regulatory sequences, ribonucleic acid MeSH D13.444.735.790.199 – rna, catalytic MeSH D13.444.735.790.400 – rna, guide MeSH D13.444.735.790.530 – rna, small cytoplasmic MeSH D13.444.735.790.537 – rna, small interfering MeSH D13.444.735.790.545 – rna, small nuclear MeSH D13.444.735.790.545.800 – rna, small nucleolar MeSH D13.444.735.790.560 – rna, spliced leader MeSH D13.444.735.790.878 – untranslated regions MeSH D13.444.735.790.878.880 – 3' untranslated regions MeSH D13.444.735.790.878.885 – 5' untranslated regions MeSH D13.444.735.828 – rna, viral
Although telomerase has telomerase reverse transcriptase as a catalytic subunit, regulation is accomplished by factors outside the protein. An enzyme composed of both regulatory and catalytic subunits when assembled is often referred to as a holoenzyme. For example, class I phosphoinositide 3-kinase is composed of a p110 catalytic subunit and a p85 regulatory subunit. One subunit is made of one polypeptide chain. A polypeptide chain has one gene coding for it – meaning that a protein must have one gene for each unique subunit.
Aerobic exercise § History Bodybuilding § History Exercise § History Exercise physiology § History Exercise trends Fitness boot camp § History Fitness culture Outdoor fitness § History Physical culture
Alongside promotions of general law enforcement and upgrades to courts, the package also provided funding for strengthening the PET's activities in the North Atlantic, and provided new maritime equipment to Greenlandic and Faroese police in response to the crisis. By 19 January 2026, a total of over kr. 88 billion (US$13.7 billion) had been committed to "strengthen defense and security in the Arctic", with kr. 29 billion allocated to acquiring F-35 fighter jets alone, and kr. 27.8 billion for anti-aircraft warfare, according to the Ministry of Defence, and at that point Denmark had sent 200 additional soldiers to Greenland. On the same day, more soldiers together with the Chief of the Royal Danish Army, General Peter Harling Boysen, started arriving in Greenland, and Denmark announced that a "substantial contribution" of its armed forces would be sent there. Also on 19 January, Defence Minister Troels Lund Poulsen and Greenlandic Minister of Foreign Affairs Vivian Motzfeldt met NATO secretary general Rutte and their Nordic Security ministers in Brussels about the situation in Greenland. General Boysen said he is ready to defend Greenland. According to Boysen, the soldiers landed in Kangerlussuaq in western Greenland. On 20 January 2026, Denmark deployed additional troops to Greenland, sending dozens of soldiers and senior military leadership to the Arctic territory to reinforce its presence and participate in ongoing multinational exercises, increasing the Danish Armed Forces' personnel stationed there amid heightened international tensions.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.